^
Association details:
| Biomarker: | KRAS G12D |
|---|---|
| Cancer: | Ovarian Serous Adenocarcinoma |
| Drug: | Mektovi (binimetinib) (MEK inhibitor) + PF-07284892 (PTPN11 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
Published date:
08/04/2023
Excerpt:
A patient with KRAS G12D-mutant low-grade serous ovarian cancer underwent surgical resection and adjuvant anastrozole. For recurrent/metastatic disease...The patient continued PF-07284892 (dose decreased like the prior patients), and binimetinib was added at the approved dose. A PR (−34%) was achieved after 6 weeks of combination therapy...
DOI:
https://doi.org/10.1158/2159-8290.CD-23-0361
